BNTC Benitec Biopharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1808898 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-18.4%
TTM EPS YoY4.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-37.6%
ROA-36.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.3%
Debt / equity0.00x
Current ratio19.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-23.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $23.39M | $18.33M |
| SG&A expense | $27.80M | $23.43M |
| Operating income | -$51.19M | -$41.77M |
| Pretax income | -$45.34M | -$37.18M |
| Income tax | $0 | — |
| Net income | -$45.55M | -$37.92M |
| EBITDA | -$51.13M | -$41.70M |
| EPS (basic) | -0.98 | -1.05 |
| EPS (diluted) | -0.98 | -1.05 |
| Weighted avg. shares (diluted) | 46.56M | 36.21M |
| Balance sheet | ||
| Cash & equivalents | $179.97M | $97.86M |
| Current assets | $181.69M | $98.52M |
| PP&E, net | $178,000 | $131,000 |
| Total assets | $182.62M | $99.59M |
| Current liabilities | $5.34M | $1.80M |
| Total liabilities | $5.61M | $2.30M |
| Shareholders' equity | $177.01M | $97.30M |
| Shares outstanding | 34.42M | 26.25M |
| Cash flow statement | ||
| Operating cash flow | -$16.52M | -$23.59M |
| Capital expenditure | $105,000 | $18,000 |
| Free cash flow | -$16.62M | -$23.61M |
| Investing cash flow | -$105,000 | -$18,000 |
| Financing cash flow | $98.98M | $70.48M |
| Depreciation & amortization | $58,000 | $66,000 |
| Stock-based compensation | $26.41M | $17.43M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.